Literature DB >> 20856704

ASCO Clinical Practice Guidelines: Past, Present and Future.

Gary H Lyman.   

Abstract

Year:  2008        PMID： 20856704      PMCID： PMC2794025          DOI： 10.1200/JOP.0851501

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  11 in total

Review 1.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

Authors:  David G Pfister; David H Johnson; Christopher G Azzoli; William Sause; Thomas J Smith; Sherman Baker; Jemi Olak; Diane Stover; John R Strawn; Andrew T Turrisi; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2003-12-22       Impact factor: 44.544

2.  ASCO Clinical Practice Guidelines and Beyond.

Authors:  Gary H Lyman
Journal:  J Oncol Pract       Date:  2007-11       Impact factor: 3.840

3.  Clinical Practice Guidelines in Oncology: Translating Evidence Into Practice (and back).

Authors:  Antonio C Wolff; Christopher E Desch
Journal:  J Oncol Pract       Date:  2005-11       Impact factor: 3.840

Review 4.  Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis.

Authors:  Theodore Kim; Armando E Giuliano; Gary H Lyman
Journal:  Cancer       Date:  2006-01-01       Impact factor: 6.860

5.  Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update.

Authors:  J Douglas Rizzo; Mark R Somerfield; Karen L Hagerty; Jerome Seidenfeld; Julia Bohlius; Charles L Bennett; David F Cella; Benjamin Djulbegovic; Matthew J Goode; Ann A Jakubowski; Mark U Rarick; David H Regan; Alan E Lichtin
Journal:  J Clin Oncol       Date:  2007-10-22       Impact factor: 44.544

Review 6.  American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.

Authors:  Ethan M Basch; Mark R Somerfield; Tomasz M Beer; Michael A Carducci; Celestia S Higano; Maha H A Hussain; Howard I Scher
Journal:  J Clin Oncol       Date:  2007-10-09       Impact factor: 44.544

7.  American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays.

Authors:  Deborah Schrag; Harinder S Garewal; Harold J Burstein; David J Samson; Daniel D Von Hoff; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2004-08-02       Impact factor: 44.544

8.  Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer.

Authors:  Deborah Schrag; Sheryl Rifas-Shiman; Leonard Saltz; Peter B Bach; Colin B Begg
Journal:  J Clin Oncol       Date:  2002-10-01       Impact factor: 44.544

Review 9.  A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications.

Authors:  Nicole M Kuderer; Alok A Khorana; Gary H Lyman; Charles W Francis
Journal:  Cancer       Date:  2007-09-01       Impact factor: 6.860

Review 10.  Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

Authors:  Nicole M Kuderer; David C Dale; Jeffrey Crawford; Gary H Lyman
Journal:  J Clin Oncol       Date:  2007-07-20       Impact factor: 44.544
View more
  2 in total

1.  Current Issues Regarding ASCO Guideline Implementation.

Authors:  Edward P Balaban
Journal:  J Oncol Pract       Date:  2009-01       Impact factor: 3.840

2.  Health technology assessment and private payers' coverage of personalized medicine.

Authors:  Julia R Trosman; Stephanie L Van Bebber; Kathryn A Phillips
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.